Advaxis (ADXS) Announces Earnings Results, Beats Expectations By $0.06 EPS

Advaxis (NASDAQ:ADXS) posted its earnings results on Monday, March 12th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.55) by $0.06, Yahoo Finance reports. Advaxis had a negative net margin of 940.64% and a negative return on equity of 149.14%. The firm had revenue of $2.06 million for the quarter, compared to analyst estimates of $3.03 million.

Shares of Advaxis stock traded down $0.01 on Thursday, reaching $1.75. The stock had a trading volume of 624,139 shares, compared to its average volume of 1,123,157. Advaxis has a 1 year low of $1.51 and a 1 year high of $9.55. The company has a market cap of $85.27, a price-to-earnings ratio of -0.76 and a beta of 1.19.

Several brokerages have recently commented on ADXS. Cantor Fitzgerald set a $19.00 target price on shares of Advaxis and gave the company a “buy” rating in a report on Friday, December 22nd. ValuEngine upgraded shares of Advaxis from a “strong sell” rating to a “sell” rating in a research report on Friday, February 2nd. Finally, HC Wainwright set a $23.00 price target on shares of Advaxis and gave the company a “buy” rating in a research report on Wednesday, December 27th.

ILLEGAL ACTIVITY NOTICE: This news story was originally posted by BBNS and is the property of of BBNS. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international copyright laws. The correct version of this news story can be viewed at https://baseballnewssource.com/2018/04/05/advaxis-adxs-issues-quarterly-earnings-results/2029006.html.

Advaxis Company Profile

Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.

Earnings History for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.

 




Latest News

Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Marlins vs Dodgers sets a 10-year record in MGM sportsbooks
Strikeouts Once Again Plaguing Cubs
Strikeouts Once Again Plaguing Cubs
Atlanta Braves: A Mix of Young and Old
Atlanta Braves: A Mix of Young and Old
Major League Baseball is Back and Astros Favored to Repeat
Major League Baseball is Back and Astros Favored to Repeat
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Jim Kaat: Baseball Would Be Helped by Shortening Game to Seven Innings
Mets Leave Runner Stranded After Batting Out of Order
Mets Leave Runner Stranded After Batting Out of Order


Leave a Reply

 
© 2006-2018 BBNS.